Navigation Links
Indevus Pharmaceuticals Announces Definitive Merger Agreement With Endo Pharmaceuticals
Date:1/5/2009

ial sale of NEBIDO.

The second Contingent Cash Payment relates to the octreotide implant and consists of $1.00 per share to be paid in the event that, within four (4) years of the closing of the tender offer, octreotide is approved by the FDA for marketing and sale for the treatment of acromegaly or carcinoid syndrome.

The tender offer is expected to commence within 5 days of the signing of the Merger Agreement and will remain open for 45 calendar days, subject to extension under certain circumstances. The tender offer closing is conditioned on the tender of a majority of the outstanding shares of Indevus' common stock, antitrust clearance and other customary closing conditions. The executive officers and directors of Indevus and certain of their affiliates, have agreed to tender approximately 4.7% of Indevus' outstanding shares in the tender offer.

UBS Securities LLC advised Indevus and provided a fairness opinion to Indevus' board of directors. Burns & Levinson LLP acted as legal counsel to Indevus.

Conference call and webcast

The live call may be accessed by dialing 800-561-2601 from the U.S. and Canada, and 617-614-3518 from international locations. The participant passcode is 42185623. Investors are advised to dial into the call at least ten minutes prior to the call to register. A replay of the call will be available beginning at 11:00 AM on January 6, 2009 and lasting until 12:00 AM on February 4, 2009. To access the replay, please dial 888-286-8010 from the U.S. and Canada, and 617-801-6888 from international locations, using the passcode 94686397.

The press release and the live webcast will be accessible by visiting the Investors section of the Company's website, http://www.indevus.com. An archived version of the call will be accessible at the same web address for 30 days following the li
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Endo Pharmaceuticals to Acquire Indevus Pharmaceuticals
2. Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results
3. Indevus Pharmaceuticals Provides Update on NEBIDO(R) NDA Status
4. Indevus Pharmaceuticals Licenses European Rights for VANTAS(R) to Orion Corporation
5. Indevus Pharmaceuticals Announces Retirement Plans For Its CEO and Chairman
6. Indevus To Announce First Quarter Fiscal 2008 Financial Results On Thursday, February 7, 2008
7. Indevus Pharmaceuticals To Present at RBC Capital Markets Conference
8. FDA Accepts New Drug Application for NEBIDO(R) Submitted by Indevus
9. Indevus Pharmaceuticals to Present at Upcoming Investor Conferences
10. Alexion Pharmaceuticals and PDL BioPharma Resolve Patent Dispute
11. Watson Pharmaceuticals Receives FDA Approval for Mint Coated Nicotine Gum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/17/2010)... sepsis, and other potentially deadly infections long has focused ... But new research from the University of Utah and ... overeager inflammatory response to infection may help save more ... in Science Translational Medicine , researchers led by ... professor of internal medicine and director of the Molecular ...
(Date:3/17/2010)... March 17 Marianjoy Rehabilitation ... Planning, John Brady , DHA, has been ... Persons with Disabilities Task Force. The Task Force ... to determine what changes, recommendations, and innovations may ... for persons with disabilities. These recommendations will then ...
(Date:3/17/2010)... -- The National Association of Professional Insurance Agents (PIA) has named Louisiana Congressman Charlie Melancon its 2010 Legislator of the ... ... , ... ... ...
(Date:3/17/2010)... -- City Harvest Food Council members and chefs ... Caminos), Lou Elrose (Wildwood Barbeque), Ivan ... Green Table), and Jorge Collazo (SchoolFood executive ... Tuesday March 16, 2010 , for lunch to ... Nutrition Act with priorities outlined by the NYC Alliance ...
(Date:3/17/2010)... of cancer treatment, skin care may seem like a ... Wilmot Cancer Center knew that skin issues were a ... therapy, and through research she discovered that routine advice ... , Her findings, which have been published in the ... change locally and across the country. , "We,ve had ...
Breaking Medicine News(10 mins):Health News:Targeting blood vessels, immune system may offer way to stop infection-caused inflammation 2Health News:Targeting blood vessels, immune system may offer way to stop infection-caused inflammation 3Health News:Marianjoy Vice President Named to Illinois' Disabilities Task Force 2Health News:Professional Insurance Agents Name Rep. Charlie Melancon 2010 Legislator of the Year 2Health News:Professional Insurance Agents Name Rep. Charlie Melancon 2010 Legislator of the Year 3Health News:Professional Insurance Agents Name Rep. Charlie Melancon 2010 Legislator of the Year 4Health News:City Harvest Food Council Chefs Meet With Harlem Students For Lunch & Travel to Washington to Ask Congress to Invest in Child Nutrition 2Health News:City Harvest Food Council Chefs Meet With Harlem Students For Lunch & Travel to Washington to Ask Congress to Invest in Child Nutrition 3Health News:City Harvest Food Council Chefs Meet With Harlem Students For Lunch & Travel to Washington to Ask Congress to Invest in Child Nutrition 4Health News:Nurses' research settles a common cancer concern: Skin care 2Health News:Nurses' research settles a common cancer concern: Skin care 3
... theory for how delusions arise and why they persist. ... an in-depth analysis of patients with certain delusions and ... the frontal lobe and right hemisphere of the human ... the right hemisphere, leads to the over compensation by ...
... Directors,of The Procter & Gamble Company (NYSE: PG ... on the Common Stock and on the Series A and,Series ... payable on,or after February 17, 2009 to shareholders of record ... The company has been paying dividends without ...
... 13 Born no larger than a ballpoint pen at ... been named the 2009 National Ambassador for the March of ... Leesburg, Virginia, was born very early at 25 weeks, weighing ... given only a 5 percent chance of survival. During her ...
... most states neglect preventing tobacco-caused illness , , TUESDAY, Jan. ... the U.S. government consistently failing grades for not protecting ... the American Lung Association,s State of Tobacco Control ... states failed to enact critical policy measures, such as ...
... Blood Drain NEW YORK, Jan. 13 New York ... York City, Long Island, Hudson Valley and New Jersey) ... Hospital demand for blood (needed for emergency care and ... blood donation have been below forecast. Blood supplies ...
... to patients and medical work to qualified employees. In ... Neeltje van den Berg and coauthors from Greifswald and ... edition of Deutsches rzteblatt International ( Dtsch ... in the age structure in Germany has had major ...
Other Medicine News:Health News:Delusions associated with consistent pattern of brain injury 2Health News:Delusions associated with consistent pattern of brain injury 3Health News:Micro-Preemie Survives to Become March of Dimes 2009 National Ambassador 2Health News:Micro-Preemie Survives to Become March of Dimes 2009 National Ambassador 3Health News:U.S. Flunks on Tobacco Control Report Card 2Health News:U.S. Flunks on Tobacco Control Report Card 3Health News:U.S. Flunks on Tobacco Control Report Card 4Health News:Blood Emergency: Blood Supply Tips Into Danger Zone 2Health News:Blood Emergency: Blood Supply Tips Into Danger Zone 3Health News:Blood Emergency: Blood Supply Tips Into Danger Zone 4Health News:Blood Emergency: Blood Supply Tips Into Danger Zone 5
(Date:3/17/2010)... states to settle a whistleblower lawsuit that exposed an alleged kickback scheme by the pharmaceutical company to boost its sales of Kadian, a prescription painkiller. , ... ... ... ... "Patients need to know their doctors are prescribing drugs ...
(Date:3/17/2010)... 12 month follow up data from real world patients demonstrated long term clinical efficacy of the company,s Genous Bio-engineered R stent. , ... ... ... ... Margo Klomp , M.D., of the Academic Medical Center (AMC) in ...
(Date:3/17/2010)... DIEGO , March 17 ... announced that it has initiated a pivotal Phase ... controlled-release formulation of hydrocodone without acetaminophen.  ZX002 is ... severe pain in individuals who require around-the-clock opioid ... the most widely prescribed drug in the ...
Breaking Medicine Technology:Whistleblower Kickback Case Against Alpharma Results In $42.5 Million Recovery for U.S. and States 2Whistleblower Kickback Case Against Alpharma Results In $42.5 Million Recovery for U.S. and States 3Data Presented at ACC/i2 Summit Demonstrate Impressive Long Term Clinical Outcomes in Real World Patients Treated with OrbusNeich's Genous(TM) Bio-engineered R stent(TM) 2Data Presented at ACC/i2 Summit Demonstrate Impressive Long Term Clinical Outcomes in Real World Patients Treated with OrbusNeich's Genous(TM) Bio-engineered R stent(TM) 3Data Presented at ACC/i2 Summit Demonstrate Impressive Long Term Clinical Outcomes in Real World Patients Treated with OrbusNeich's Genous(TM) Bio-engineered R stent(TM) 4Zogenix Initiates Pivotal Phase 3 Clinical Trial for Novel Formulation of Oral Controlled-Release Hydrocodone 2Zogenix Initiates Pivotal Phase 3 Clinical Trial for Novel Formulation of Oral Controlled-Release Hydrocodone 3Zogenix Initiates Pivotal Phase 3 Clinical Trial for Novel Formulation of Oral Controlled-Release Hydrocodone 4The Secret of Happiness 49884 1The Secret of Happiness 49884 2The Secret of Happiness 49884 3First Coast Medicare to Provide Case by Case Reimbursement for the Renessa 28R 29 Treatment for Incontinence in Women 49879 1First Coast Medicare to Provide Case by Case Reimbursement for the Renessa 28R 29 Treatment for Incontinence in Women 49879 2First Coast Medicare to Provide Case by Case Reimbursement for the Renessa 28R 29 Treatment for Incontinence in Women 49879 3Mercy Health Plans Launches MercyOne Connect 28TM 29 49874 1Mercy Health Plans Launches MercyOne Connect 28TM 29 49874 2
... VRUS ), Roche (SWX: ROG) and InterMune, Inc. ... have been dosed in an innovative clinical,trial in patients ... (run in centers in Australia and New Zealand) is ... molecules in the absence,of interferon., The initial study ...
... NOVATO, Calif., Nov. 10 Raptor,Pharmaceuticals Corp. ... today announced that the Company has entered ... d,Angers ("CHU d,Angers") of France to,evaluate Raptor,s ... Phase II clinical trial in patients with ...
Other Medicine Technology:Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C 2Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C 3Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C 4Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C 5Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire d'Angers for Phase II Clinical Trial in Huntington's Disease 2Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire d'Angers for Phase II Clinical Trial in Huntington's Disease 3Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire d'Angers for Phase II Clinical Trial in Huntington's Disease 4Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire d'Angers for Phase II Clinical Trial in Huntington's Disease 5Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire d'Angers for Phase II Clinical Trial in Huntington's Disease 6
QIAvac 96 is designed for efficient processing of QIAGEN 96-well plates....
Holder for QIAGEN 96-well plates, for use with QIAvac 96;...
For monitoring vacuum pressure, suitable for use with all QIAvac manifolds;...
DNA/RNA preparation in 8-multi channels...
Medicine Products: